Form 4: Director David Pyott Increases Alnylam Equity Stake

Alnylam Pharmaceuticals Director David E.I. Pyott acquired 671 restricted stock units and 1,441 stock options as part of an annual equity grant.

Summary

• Director David E.I. Pyott received an equity grant consisting of 671 restricted stock units (RSUs) and 1,441 stock options.
• The RSUs and options were granted under the Second Amended and Restated 2018 Stock Incentive Plan.
• The awards are scheduled to vest in full on the first anniversary of the grant date, May 20, 2027, or upon earlier retirement/resignation under specific conditions.
• The exercise price for the stock options is $298.48 per share.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure of standard director compensation, which carries a neutral sentiment regarding company performance.

Positives

• Director demonstrates continued alignment with shareholder interests through the acceptance of equity-based compensation.
• The grant structure incentivizes long-term retention and performance through a one-year vesting schedule.

Negatives

• The issuance of additional equity awards results in minor dilution to existing shareholders.

Risks

• The value of the granted equity is subject to market volatility and the future performance of Alnylam Pharmaceuticals common stock.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on the disclosure of director equity compensation.

Industry Context

StockSavvy.ai notes that standard annual equity grants to non-employee directors are common practice in the biotechnology sector to ensure board member alignment with long-term corporate strategy.

Comparison to Industry Standards

• The grant of RSUs and options is consistent with standard compensation packages for independent directors at mid-to-large cap biotechnology firms.
• The one-year vesting period is a standard industry practice for annual director equity awards.

Stakeholder Impact

• Minor dilution impact on existing shareholders due to the issuance of new equity awards.

Next Steps

• Vesting of the granted RSUs and stock options on May 20, 2027.

Key Dates

Keywords

Alnylam Pharmaceuticals, ALNY, Insider Trading, Form 4, Equity Compensation, Director Compensation